HOME >> MEDICINE >> NEWS
Predicting the outcome of drug-induced liver disease

Drug-induced liver disease (DILD), a potential complication seen with some medications, is usually not life-threatening, but may occasionally be more severe with a high mortality, requiring a liver transplant in selected cases. During the last decade, drug-induced liver injury has led to the withdrawal of a number of drugs from the market. Hy's rule, an observation by the late Dr. Hyman Zimmerman, states that the combination of high liver cell damage as measured by liver enzymes and jaundice induced by a drug is associated with a fatality rate of 10-50 percent. This rule has been advocated by the FDA for assessing the liver toxicity of newly developed drugs, but it has never been scientifically validated.

A study by Einar Bjrnsson, M.D., Ph.D. and Rolf Olsson, M.D., Ph.D. of the department of internal medicine at Sahlgrenska University Hospital in Gothenburg, Sweden and published in the August 2005 issue of Hepatology, analyzed reports of suspected drug-induced liver injury received by the Swedish Adverse Drug Reactions Advisory Committee (SADRAC) in order to evaluate the validity of Hy's rule and determine what factors might predict the outcome of different forms of DILD.

Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD), published by John Wiley & Sons, Inc. is available online via Wiley InterScience at http://www.interscience.wiley.com/journal/hepatology.

A total of 784 reports were included in the analysis, each with bilirubin greater than twice upper normal limits and ALT (a liver enzyme that when elevated indicates liver damage) greater than three times upper normal limits. Of these, 409 cases had hepatocellular or HC liver injury (damage to liver cells); while 206 had cholestatic (bile flow) injury and 169 had mixed liver injury. In 633 cases, one drug was suspected of causing the liver injury, while in 151 cases more t
'"/>

Contact: Amy Molnar
amolnar@wiley.com
John Wiley & Sons, Inc.
18-Jul-2005


Page: 1 2

Related medicine news :

1. Predicting danger of flu pandemic rests on differences in affected population, says O.R. Forum
2. Predicting the quality of life for older adults
3. Predicting the risk of rheumatoid arthritis for early arthritis patients
4. Predicting an answer to the threat of flooding
5. Predicting outcomes for kidney transplant patients
6. Predicting successful outcomes in living-donor liver transplants
7. Predicting cardiovascular problems in liver transplant patients
8. Predicting the risk of death in patients with known coronary artery disease
9. Predicting the future of primary care in England
10. Predicting serious cardiac outcomes
11. Comparison of obstetric outcomes between on-call and patients own obstetricians

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Predicting the outcome drug induced liver disease

(Date:7/23/2014)... The routine use of a molecular ... likelihood of performing the correct initial surgery for ... from the University of Pittsburgh Cancer Institute (UPCI), ... at the UPMC/UPCI Multidisciplinary Thyroid Center and other ... getting the correct initial surgery by 30 percent, ...
(Date:7/23/2014)... FL (PRWEB) July 23, 2014 Men ... pay higher premiums for life insurance based on national ... cheap life insurance rates search to its comprehensive tool ... at http://quotespros.com/life-insurance.html . , Providers that are ... selected, sorted and reviewed in one or two clicks. ...
(Date:7/23/2014)... near Sellafield or Dounreay since the 1990s are not ... research published in the British Journal of Cancer ... Research Group at the University of Oxford and from ... among those who were under 25 and living near ... in cancer incidence from 1991-2006 between those living near ...
(Date:7/23/2014)... New York, New York (PRWEB) July 23, 2014 ... that the use of a power morcellator ( http://www.injurybeacon.com/power-morcellator/ ... uterine sarcoma and other cancers throughout a woman’s body, ... on July 22nd in the Journal of the American ... hysterectomy using a power morcellator at 500 U.S. hospitals ...
(Date:7/23/2014)... Asking patients if a suspicious skin lesion is ... spot is likely to be cancerous, according to a ... the Department of Dermatology at Temple University School of ... Dermatology on July 23, 2014, found that nearly ... by itching, while 28.2 percent involve pain. Non-melanoma skin ...
Breaking Medicine News(10 mins):Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 2Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 3Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 4Health News:Cheap Life Insurance Rates for Married Couples Added to Search System at Insurer Portal Online 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2
(Date:7/23/2014)...  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a ... expertise in opioid antagonists, announced today that it ... with respect to its naloxone-based opioid overdose reversal ... has received an additional commitment from the National ... National Institutes of Health ("NIH"), to fund a ...
(Date:7/23/2014)... CITY, Calif. , July 23, 2014  Cardica, Inc. ... release financial results for its fiscal fourth quarter and year ... the markets close. Cardica,s management will host a conference call ... and provide an update on the company,s business. ... August 7, 2014, at 4:30 p.m. Eastern Time via phone, ...
(Date:7/23/2014)... Colo. , July 23 2014 Ampio ... of its new headquarters, manufacturing and research facility: ... CO 80112 Direct: (720) 437-6500 ... labor efficient, pharmaceutical drug manufacturing facility will be fully ... produce the first batches of Ampion TM necessary ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3Cardica to Announce Fiscal 2014 Fourth Quarter and Full Year Financial Results on Thursday, August 7, 2014 2Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2
Cached News: